BioMarin Teams Use Genetic Expertise and Computational Tools to Target More Common Conditions
For geneticist Daniel Gaffney, becoming an expert in how genes influence human health was not enough. His drive to improve lives with this knowledge led him to BioMarin, where he found a shared commitment to translating scientific advances into medicines that solve genetic problems. Since joining the company earlier this year, Dan has helped its […]
Raising a Child with Hemophilia: BioMarin Employee Jess Klass Shares Her Story
After growing up with a brother living with hemophilia A and working in roles supporting the bleeding disorder community for years, Jess Klass thought she knew everything there was to know about hemophilia.
BioMarin Pioneer Honored through New Building Name and Book Launch
“BioMarin stands on the precipice of a gene therapy revolution, and this is a dream come true,” said Robert A. Baffi, Ph.D., retired president of Global Manufacturing and Technical Operations, at a ceremony announcing the renaming of our gene therapy manufacturing facility in his honor and the launch of his new book on how to […]
At the Intersection of Science and Art
It should not come as a surprise to anyone that art and science are siblings. Faced with a lump of clay, a potter has a world of infinite possibility at their beck and call. Every revolution of the potter’s wheel is the beginning of a journey, of an experiment. With much trial and error, with […]
BioMarin Scientist Spotlight: Drs. Sylvia Fong & Soumi Gupta Discuss the Significance of AAV Therapies
By interrogating the human genome, we’ve designed therapies that address the root cause of genetic disease. That’s a guiding principle for how we approach our research at BioMarin, and nowhere is that more true than in our work researching gene therapy. As part of our commitment to expanding our technical expertise, we’re looking into many […]
Independent Research Presented at Pediatric Endocrine Society Annual Meeting
BioMarin congratulates Dr. Andrew Dauber, Chief of Endocrinology at Children’s National Hospital in Washington, D.C., who has recently presented independent research to study a BioMarin therapy, in selected genetic causes of short stature.